Seelos Therapeutics To Test Trehalose In Patients With Rare Movement Control DisorderBenzinga • 11/08/21
Seelos Therapeutics Announces FDA Acceptance of Investigational New Drug Application and Grant of Fast Track Designation for SLS-005 (IV Trehalose) for the Treatment of Spinocerebellar AtaxiaPRNewsWire • 11/08/21
Why This Seelos Therapeutics Analyst Is Turning Bullish On Potential Trial ResultsBenzinga • 09/27/21
Seelos Therapeutics Shares Gain On FDA Approval To Add SLS-005 Regimen In HEALEY ALS TrialBenzinga • 09/21/21
Seelos Therapeutics Announces Appointment of Margaret Dalesandro to the Board of DirectorsPRNewsWire • 09/02/21
Seelos Therapeutics Announces Positive In Vivo Data Demonstrating Down-Regulation of SNCA mRNA and Protein Expression from a Gene Therapy Study of SLS-004 Utilizing CRISPR-dCas9 for Parkinson's Disease PathologyPRNewsWire • 07/07/21
Seelos Therapeutics Doses First Patient in Part 2 of a Registrational Study of SLS-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior in Patients with Major Depressive DisorderPRNewsWire • 07/06/21